Covid-19 Updates | Targeted Protein Degradation Enabling Technologies Market is anticipated to be worth over USD 3.3 billion by 2030 | #targeted Protein Degradation

Economics and Trade

Covid-19 Updates | Targeted Protein Degradation Enabling Technologies Market is anticipated to be worth over USD 3.3 bil

Targeted protein degradation has emerged as a revolutionary pharmacological concept that presents both viable and versatile drug development opportunities and is anticipated to introduce a new paradigm in modern healthcare

Covid-19 Updates | Cell Therapy Manufacturing Market is estimated to reach close to USD 11 Billion by 2030 | #cell Therapy Manufacturing Market

Economics and Trade

Covid-19 Updates | Cell Therapy Manufacturing Market is estimated to reach close to USD 11 Billion by 2030

Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers

Covid-19 Updates | Biopharmaceutical Contract Manufacturing Market is estimated to be worth USD 13.9 billion in 2030 | #biopharmaceutical Contract Manufacturing

Economics and Trade

Covid-19 Updates | Biopharmaceutical Contract Manufacturing Market is estimated to be worth USD 13.9 billion in 2030

Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages

Covid-19 Updates | Antibody Contract Manufacturing Market is estimated to be worth USD 17 billion in 2030 | #antibody Contract Manufacturing

Economics and Trade

Covid-19 Updates | Antibody Contract Manufacturing Market is estimated to be worth USD 17 billion in 2030

The benefits of engaging a CMO or CDMO for antibody development and production extend beyond fulfilling the needs of small companies; access to new technologies and operational flexibility are attractive attributes to larger players as well

Subcutaneous Biologic Drugs and Affiliated Technologies Market is projected to be worth over USD 180 billion by 2030 | #subcutaneous Biologic Drugs

Economics and Trade

Subcutaneous Biologic Drugs and Affiliated Technologies Market is projected to be worth over USD 180 billion by 2030

More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development, for the treatment of a wide variety of disease indications, claims Roots Analysis